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Familial Hypercholesterolemia: 
A Dangerous Disease in Lewiston/Auburn, Maine
• Autosomal dominant defect in hepatic LDL receptor preventing LDL uptake -> increased 
serum LDL -> accelerated ASCVD (risk 2.5-10x greater than general population) [1]
• According to a study in the Netherlands, a heterozygous FH-patient of 35 years can 
reach the cumulative LDL cholesterol of a non-FH 55 y/o[2] ->  greater risk for premature 
ASCVD
• US prevalence: 1 in 250 people [3]
• In Lewiston/Auburn, ME : 1 in 30-50 people (10-fold increase in prevalence) [4]
– High prevalence amongst the Franco-American ethnic population-> improving 
awareness about the disease and its sequelae amongst this population is an area 
of need [5]
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Relative Risk of Familial Hypercholesterolemia
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Public health implications of FH: US and in L/A, Maine
General CVD burden:
US, 2016: $555 billion in CVD-related costs, estimated $1.1 trillion in 2035 [6]
-FH pts factor into this cost early in life and frequently
US: Family-based CASCADE Screening [1]
-most FH patients have not been treated to established goals
-Identifies FH pts to help ensure treatment prior to developing ASCVD 
-Formal cost-effectiveness has not been evaluated; studies in the Netherlands evaluated cost 
effectiveness at $8,700/year added to patient’s life [7]
Central Maine Heart and Vascular Institute (CMHVI), Lewiston
-Maine CDC last reported direct costs of Heart Disease in 2003 as $230 million[8]
-Specific estimation of FH burden in ME has not been established - a clear area for future work
-Aforementioned CASCADE screening is being implemented at Central Maine Medical Center
-Weekly lipid clinic at CMHVI: Specialty clinic for patients with all dyslipidemias
-Outreach work by local cardiologist and disease expert Dr. McCann to the Franco Center to 
create awareness of the disease established through grant work
Local community members aware of the disease, its course, and potential sequelae 
endorse the need for improved awareness at the local, community level
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Community Health Perspectives:
Dr. McCann and Dr. Picker
“This is one of the few genetic conditions that can be successfully treated, but 
cannot be successfully treated by diet and exercise alone. This needs medical 
treatment”
-Dr. Dervilla McCann, MD, MPH, Cardiology and Population Health
Central Maine Medical Center, Lewiston, ME
“The level of public education on FH is encouraging and better now than it 
has been 5 years ago. However, the fact that I see patients don’t seem to 
know the full effects of the disease and its implications is surprising, because 
this situation requires them to be their own health advocates.”
-Dr. Bethany Picker, MD, Family Medicine 
Central Maine Medical Center, Lewiston, ME
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Intervention: Focus Group Questions 
and Directed Educational Materials
1) Gather qualitative data from population of interest at local community 
center (Gendron Franco Center) through small, directed focus groups
2) Evaluate and synthesize information to identify areas where awareness is 
strong and areas of improvement
3) Create and deliver handout to Franco-American Center designed to address 
areas of need in knowledge of disease
Question A: What are your perceptions of the disease (FH) previously mentioned 
to you by community cardiologist Dr. McCann? 
What do you know about it?
Question B: What suggestions can you think of about how primary care providers 
can better serve these patients?
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Results and Analysis 
Sample: ~ 5 focus groups of 3-5 Franco-American patrons, Gendron Franco Center, Auburn, ME
Question A Takeaways
Areas of strength:
1) Consistent recollection of the disease once reminded of Dr. McCann (who first presented 
information)
2) Awareness that Franco-Americans are an increased risk group for cardiovascular disease
-shows effectiveness of prior outreach work by Dr. McCann directed towards this goal
3) Those who had family members/friends implicated by disease had an increased likelihood to 
understand details of FH
-one woman described the disease process as: “body making bad cholesterol”, then recalled a 
friend’s son who was diagnosed at 6-7 y/o, managed on Lipitor and Niacin
-another woman recalled that her father and uncle passed away in early 30s from CVD
Areas of need:
1) Need for better basic understanding about disease (e.g. a genetic process affecting young age vs. 
non-familial HLD)
e.g. related to situations like “My dad had a heart attack at old age”
2) Self-admission of need for more knowledge 
-statements that this information was still “new” and “good to be aware of”
Slide 6A
Results and Analysis (continued)
Question B Responses
Areas of strength:
1) Recognizing importance of diet and exercise as reinforced by doctor during healthcare visits
-“I just don’t follow my diet and exercise like I should”
2) Cultural and socioeconomic respect for authority, especially physicians
-Emphasis on a need to “ just listen to what your doctor tells you” 
3) Demonstrating a desire for a sense of control and to be proactive in treating their disease
- After being reminded about the disease, one woman said: “patients need to be shown how 
to treat their condition” 
Areas of need:
1) A desire to have access to FH-related information through existing healthcare resources
-Former nurse: “have this information available in the office! Even for people without 
the disease, so all are informed.”
2) Education regarding role of diet and exercise in treatment of FH
3) Knowledge about how the disease can be controlled (i.e. medications)
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Limitations and Proposed Evaluation of 
Effectiveness
Limitations
• Sample size bias
– Possible skewed evaluation of strengths and areas of need
• Location
– Alternative settings could be more conducive to varied patient interviews
• Qualitative data
– Evaluation of improvement based on data could require either quantitative 
data or creation of a metric to assess this qualitative data
Evaluation of Effectiveness
• Formal evaluation of effectiveness could be ideally assessed by survey 
• Assess knowledge of disease as compared to non-familial HLD, its risk 
factors, and what measures patients can take to prevent sequelae
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Recommendations for future 
interventions/projects
• Evaluate barriers to care of FH and other dyslipidemias for 
patients at local community centers or at primary care 
office primary care office
• Target provider perspective and produce a survey to elicit 
providers’ thoughts on areas of need in management of FH 
and associated sequelae
• Work with food pantries/food distribution centers to help 
inform underprivileged individuals with FH about healthy 
eating habits for prevention of ASCVD
• Develop intake screening questionnaire to identify 
individuals with FH who would be candidates for providing 
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